Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
39.57
+1.00 (2.59%)
Feb 21, 2025, 4:00 PM EST - Market closed
Qiagen Revenue
In the year 2024, Qiagen had annual revenue of $1.98B with 0.66% growth. Qiagen had revenue of $521.20M in the quarter ending December 31, 2024, with 2.36% growth.
Revenue (ttm)
$1.98B
Revenue Growth
+0.66%
P/S Ratio
4.37
Revenue / Employee
$331,526
Employees
5,967
Market Cap
8.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
| Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
| Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
| Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
| Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
QGEN News
- 9 days ago - QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region - Business Wire
- 16 days ago - Qiagen N.V. (QGEN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 17 days ago - QIAGEN delivers solid Q4 2024 growth ahead of outlook - Business Wire
- 18 days ago - QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent - Business Wire
- 5 weeks ago - QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million - Business Wire
- 5 weeks ago - QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast - Business Wire
- 5 weeks ago - QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase - Business Wire
- 6 weeks ago - QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples - Business Wire